Risk of Serious Infections in Patients with Ulcerative Colitis Treated with Tofacitinib Compared to Biologic Treatments in the United States

被引：0
|
作者：
Rubin, David T. [1 ]
Schreiber, Stefan [2 ]
Peyrin-Biroulet, Laurent [3 ,4 ]
Danese, Silvio [5 ]
Gianfrancesco, Milena [6 ]
Soonasra, Arif [7 ]
Sidhu, Sarah [6 ]
Vranic, Ivana [8 ]
Shelbaya, Ahmed [6 ]
Gruben, David [9 ]
Winthrop, Kevin [10 ]
Curtis, Jeffrey [11 ]
Regueiro, Miguel D. [12 ]
Dubinsky, Marla C. [13 ]
机构：
[1] Univ Chicago Med, Inflammatory Bowel Dis Ctr, Chicago, IL USA
[2] Univ Hosp Schleswig Holstein, Kiel, Germany
[3] Nancy Univ Hosp, INFINY Inst, FHU CURE, INSERM,NGERE, Vand?uvre Ies Nancy, Lorraine, France
[4] McGill Univ, Hlth Ctr, Montreal, PQ, Canada
[5] IRCCS San Raffaele Sci Inst, Milan, Lombardy, Italy
[6] Pfizer Inc, New York, NY USA
[7] Pfizer Inc, Collegeville, PA USA
[8] Pfizer Inc, Walton Oaks, England
[9] Pfizer Inc, Groton, CT USA
[10] Oregon Hlth & Sci Univ, Portland, OR USA
[11] Univ Alabama Birmingham, Birmingham, AL USA
[12] Cleveland Clin, Cleveland, OH USA
[13] Icahn Sch Med Mt Sinai, New York, NY USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2024年 / 119卷 / 10S期
关键词：
D O I：
10.14309/01.ajg.0001033604.38645.83
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
S1059
引用
收藏
页码：S746 / S746
页数：1
相关论文
共 50 条
  • [1] Risk of Myocardial Infarction, Stroke, and Thromboembolic Events in Patients With Ulcerative Colitis Treated With Tofacitinib Compared to Biologic Treatments in the United States
    Rubin, David T.
    Schreiber, Stefan
    Danese, Silvio
    Peyrin-Biroulet, Laurent
    Gianfrancesco, Milena
    Soonasra, Arif
    Sidhu, Sarah
    Vranic, Ivana
    Shelbaya, Ahmed
    Gruben, David
    Curtis, Jeffrey
    Regueiro, Miguel D.
    Dubinsky, Marla C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S745 - S746
  • [2] Incidence rate of serious infections in patients with ulcerative colitis with or without systemic therapy in the United States
    Liang, Huifang
    Danwada, Raghava X.
    Zhang, Dongmu
    Duan, Rachel W.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 481 - 481
  • [3] Analysis of Infections of Interest in Patients Treated with Tofacitinib in the Ulcerative Colitis Clinical Program
    Chiorean, Michael V.
    Ha, Christina
    Armuzzi, Alessandro
    Lawendy, Nervin
    Mundayat, Rajiv
    Salese, Leonardo
    Woolcott, John C.
    Su, Chinyu
    Dotan, Iris
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S406 - S406
  • [4] Clostridium difficile Infection in Patients with Ulcerative Colitis Treated with Tofacitinib in the Ulcerative Colitis Program
    Loftus, Edward V., Jr.
    Baumgart, Daniel C.
    Gecse, Krisztina
    Kinnucan, Jami A.
    Connelly, Susan B.
    Salese, Leonardo
    Su, Chinyu
    Kwok, Kenneth K.
    Woolcott, John C.
    Armuzzi, Alessandro
    INFLAMMATORY BOWEL DISEASES, 2023, 29 (05) : 744 - 751
  • [5] Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
    Michael Chiorean
    Christina Ha
    Peter Hur
    Puza P. Sharma
    David Gruben
    Nabeel H. Khan
    Digestive Diseases and Sciences, 2023, 68 : 3985 - 3993
  • [6] Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
    Chiorean, Michael
    Ha, Christina
    Hur, Peter
    Sharma, Puza P.
    Gruben, David
    Khan, Nabeel H.
    DIGESTIVE DISEASES AND SCIENCES, 2023, 68 (10) : 3985 - 3993
  • [7] Serious infections in patients treated with immunossuppressive biologic agents
    Montane Esteva, Eva
    Hladun Alvaro, Olga
    Nunez Montero, Melani
    Barriocanal Barriocanal, Ana Maria
    Perez Acevedo, Ana Pilar
    Cardona Peitx, Gloria
    Esteve Pardo, Maria
    Blanco Rojas, Beatriz
    Valera Paloma, Julia
    Pedro-Botet Montoya, Luisa
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2022, 130 : 29 - 30
  • [8] REAL-WORLD EXPERIENCE OF USING TOFACITINIB IN ULCERATIVE COLITIS IN BIOLOGIC NAIVE AND BIOLOGIC EXPOSED PATIENTS
    Cheesbrough, Jonathan
    Sharma, Naveen
    Nassar, Islam
    Quraishi, Nabil
    GUT, 2022, 71 : A42 - A42
  • [9] Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naive and biologic exposed patients
    Cheesbrough, J.
    Quraishi, M. N.
    Sharma, N.
    Nassar, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I443 - I444
  • [10] Real-world experience of using Tofacitinib in Ulcerative Colitis in biologic naive and biologic exposed patients
    Cheesbrough, J.
    Quraishi, M. N.
    Sharma, N.
    Nassar, I.
    JOURNAL OF CROHNS & COLITIS, 2022, 16 : I443 - I444
12345